60 related articles for article (PubMed ID: 38528478)
1. Body Composition in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy.
Chaunzwa TL; Qian JM; Li Q; Ricciuti B; Nuernberg L; Johnson JW; Weiss J; Zhang Z; MacKay J; Kagiampakis I; Bikiel D; Di Federico A; Alessi JV; Mak RH; Jacob E; Awad MM; Aerts HJWL
JAMA Oncol; 2024 May; ():. PubMed ID: 38780929
[TBL] [Abstract][Full Text] [Related]
2. Obesity paradox in patients with non-small cell lung cancer undergoing immune checkpoint inhibitor therapy.
Lee JH; Kang D; Ahn JS; Guallar E; Cho J; Lee HY
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2898-2907. PubMed ID: 37964713
[TBL] [Abstract][Full Text] [Related]
3. Differential Effect of Consolidative Thoracic Radiation Therapy in Extensive-Stage Small Cell Lung Cancer Based on Sex.
Jairam V; Soulos PR; K C M; Gross CP; Slotman BJ; Chiang AC; Park HS
Adv Radiat Oncol; 2024 Apr; 9(4):101413. PubMed ID: 38778819
[TBL] [Abstract][Full Text] [Related]
4. High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.
Dai L; Tan Q; Li L; Lou N; Zheng C; Yang J; Huang L; Wang S; Luo R; Fan G; Xie T; Yao J; Zhang Z; Tang L; Shi Y; Han X
Mol Cell Proteomics; 2024 May; 23(5):100749. PubMed ID: 38513890
[TBL] [Abstract][Full Text] [Related]
5. Association between sex and outcomes in patients with non-small-cell lung cancer receiving combination chemoimmunotherapy as a first-line therapy: a systematic review and meta-analysis of randomized clinical trials.
Takada K; Shimokawa M; Mizuki F; Takamori S; Takenaka T; Miura N; Shikada Y; Yoshizumi T
Eur J Med Res; 2022 Aug; 27(1):157. PubMed ID: 35999618
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapy for advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cameron LB; Hitchen N; Chandran E; Morris T; Manser R; Solomon BJ; Jordan V
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013453. PubMed ID: 34994987
[TBL] [Abstract][Full Text] [Related]
7. A lack of association between BMI and chemoimmunotherapy efficacy in advanced non-small cell lung cancer: Secondary analysis of the IMpower150 and IMpower130 clinical trials.
Li LX; Socinski MA; Kichenadasse G; Karapetis CS; Shahnam A; McKinnon RA; Rowland A; Hopkins AM; Sorich MJ
BMC Cancer; 2024 Mar; 24(1):379. PubMed ID: 38528478
[TBL] [Abstract][Full Text] [Related]
8. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
9. Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations.
Cortellini A; Ricciuti B; Vaz VR; Soldato D; Alessi JV; Dall'Olio FG; Banna GL; Muthuramalingam S; Chan S; Majem M; Piedra A; Lamberti G; Andrini E; Addeo A; Friedlaender A; Facchinetti F; Gorría T; Mezquita L; Hoton D; Valerie L; Nana FA; Artingstall J; Comins C; Di Maio M; Caglio A; Cave J; McKenzie H; Newsom-Davis T; Evans JS; Tiseo M; D'Alessio A; Fulgenzi CAM; Besse B; Awad MM; Pinato DJ
J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35173031
[TBL] [Abstract][Full Text] [Related]
10. Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non-Small Cell Lung Cancer.
Kichenadasse G; Miners JO; Mangoni AA; Rowland A; Hopkins AM; Sorich MJ
JAMA Oncol; 2020 Apr; 6(4):512-518. PubMed ID: 31876896
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
Pathak R; De Lima Lopes G; Yu H; Aryal MR; Ji W; Frumento KS; Wallis CJD; Klaassen Z; Park HS; Goldberg SB
Cancer; 2021 Mar; 127(5):709-719. PubMed ID: 33119177
[TBL] [Abstract][Full Text] [Related]
12. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials.
Socinski MA; Jotte RM; Cappuzzo F; Nishio M; Mok TSK; Reck M; Finley GG; Kaul MD; Yu W; Paranthaman N; Bara I; West HJ
JAMA Oncol; 2023 Apr; 9(4):527-535. PubMed ID: 36795388
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity and Utility of Pharmaceutical Company Sharing of Individual-Participant Data Packages.
Hopkins AM; Modi ND; Abuhelwa AY; Kichenadasse G; Kuderer NM; Lyman GH; Wiese MD; McKinnon RA; Rockhold FW; Mann A; Rowland A; Sorich MJ
JAMA Oncol; 2023 Dec; 9(12):1621-1626. PubMed ID: 37796495
[TBL] [Abstract][Full Text] [Related]
14. Treatment Decisions for Resectable Non-Small-Cell Lung Cancer: Balancing Less With More?
O'Reilly D; Botticella A; Barry S; Cotter S; Donington JS; Le Pechoux C; Naidoo J
Am Soc Clin Oncol Educ Book; 2023 May; 43():e389950. PubMed ID: 37220324
[TBL] [Abstract][Full Text] [Related]
15. On the 12th Day of Christmas, a Statistician Sent to Me . .
Riley RD; Cole TJ; Deeks J; Kirkham JJ; Morris J; Perera R; Wade A; Collins GS
BMJ; 2022 Dec; 379():e072883. PubMed ID: 36593578
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
